Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 2Head & Neck 1Gynecologic 1Dermatologic 1

Conditions

Lung Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Pancreatic Neoplasms 5Ovarian Neoplasms 5Fallopian Tube Neoplasms 5Endometrial Neoplasms 5Breast Neoplasms 5Neoplasm Metastasis 4Adenocarcinoma Of Esophagus 4Triple Negative Breast Neoplasms 3Esophageal Neoplasms 3Cholangiocarcinoma 3Squamous Cell Carcinoma of Head and Neck 2Melanoma 2Esophageal Squamous Cell Carcinoma 2Colorectal Neoplasms 2Carcinoma, Transitional Cell 2Brenner Tumor 2Urinary Bladder Neoplasms 1Small Cell Lung Carcinoma 1Sinonasal Squamous Cell Carcinoma 1Rectal Neoplasms 1Pancreatic Cystic Neoplasm 1Oropharyngeal Neoplasms 1Neoplasms 1Mouth Neoplasms 1Metastatic Pancreatic Ductal Adenocarcinoma 1Locally Advanced Cervical Adenocarcinoma 1Laryngeal Neoplasms 1Gallbladder Neoplasms 1

Interventions

Bevacizumab 26Cetuximab 24Fluorouracil 23Leucovorin 22Oxaliplatin 19pembrolizumab 18Specimen Handling 11Irinotecan 10Nivolumab 8Magnetic Resonance Spectroscopy 8atezolizumab 7Biopsy 7Pemetrexed 6Panitumumab 6Cisplatin 6Carboplatin 6trifluridine tipiracil drug combination 5fludarabine 5encorafenib 5HMPL-013 5Gemcitabine 5Folfox protocol 5Standard of Care 4Immunoglobulin G 4Disulfides 4Cyclophosphamide 4zanidatamab 3regorafenib 3fludarabine phosphate 3dehydroftorafur 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Colorectal Neoplasms × Taxes × 30 days × Clear all
NCT04083599 2026-06-02

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

Genmab

Phase 1/2 Active not recruiting
350 enrolled
DermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

NCT06607185 2026-05-26

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
750 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡